Latest News and Press Releases

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target...

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding...

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical...